RecruitingPhase 1NCT04537403

PET Detection of CCR2 in Human Atherosclerosis

Sponsor

Washington University School of Medicine

Enrollment

100 participants

Start Date

Oct 1, 2020

Study Type

INTERVENTIONAL

Conditions

Carotid atherosclerosis

Summary

: Use of novel radio-pharmaceutical 64CUDOTA-ECL1i to evaluate arterial atherosclrosis

Eligibility

Min Age: 18 YearsMax Age: 89 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine) and a drug called Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine) for people with carotid atherosclerosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 89 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGroup 1-64CU-DOTA-ECL1i (radioactive imaging medicine)

Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy

DRUGGroup 2 64CU-DOTA-ECL1i (radioactive imaging medicine)

Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart